More Ways to Connect
  LinkedIn Twitter YouTube Instagram
  RSS
Search
News
Cincinnati Children's Hospital Medical Center is an international leader in research and medical care related to infant, child and adolescent diseases.
PHOTOS: 
1

Cincinnati Children's Hospital Medical Center is an international leader in research and medical care related to infant, child and adolescent diseases.
Back Next
Publish Date: 08/11/11
Media Contact: Nick Miller, 513-803-6035
print
PDF download
RSS feed
related news
share this
Intestinal Protein Could Help Identify New Therapies for ADHD

CINCINNATI—A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating Attention Deficit Hyperactivity Disorder (ADHD) and other neuropsychiatric disorders, according to a team of scientists from UC, Cincinnati Children's Hospital Medical Center and China and reported in the Aug. 11 edition of Science

Scientists have for the last quarter century studied the intestinal membrane receptor protein guanylyl cyclase-C (GC-C) for its role in diarrheal disease and other intestinal functions, according to Mitchell Cohen, MD, U.S. author on the study and director of Gastroenterology, Hepatology and Nutrition at Cincinnati Children’s. In fact, it had been thought that GC-C was found primarily in the intestine.

In the current study, scientists in China who collaborated with Cohen discovered that the receptor is also expressed in critical areas of the brain. The senior author on the study is Minmin Luo, a researcher at the National Institute of Biological Sciences and Tsinghua University in Beijing.

Using a mouse model developed in Ralph Giannella’s, MD, laboratory at the University of Cincinnati, in which the GC-C receptor is deleted, or knocked out, the researchers found the mice exhibit hyperactivity and attention deficits. It is the first time that GC-C has been linked to neuropsychiatric disorder, according to the researchers.

"We show that the neurons selectively express GC-C and that its activation amplifies the excitatory responses mediated by other receptors on dopamine neurons in the midbrain,” says Luo. "Working through a protein kinase called PKG, GC-C activity increases brain dopamine levels and thus regulates mouse attention and activity level.”

When the researchers treated the GC-C knockout mice with amphetamine-based ADHD medication and a PKG activator, it reversed their hyperactive, inattentive behavior.

"The results indicate important behavioral and physiological functions for the GC-C/PKG signaling pathway in the brain,” says Luo. "The data also suggest new therapeutic targets for neuropsychiatric disorders related to malfunctions of midbrain dopamine receptors.”

One of the most prevalent human behavioral disorders, ADHD has been linked to imbalances in the dopamine system. The researchers note in the study that its findings— mice exhibiting reduced dopamine levels and related behavioral problems—are consistent with the biochemical characteristics of human ADHD.

"This could make the GC-C knockout mouse a good research model for ADHD and other behavioral disorders,” says Cohen. "Efforts to develop activators or inhibitors of the GC-C/PKG signaling pathway may lead to novel treatments for other disorders, such schizophrenia, Parkinson’s disease and addiction.”

The first author on the study is Rong Gong, who is in the joint graduate program of Peking Union Medical College and the National Institute of Biological Sciences in Beijing. Other institutions collaborating on the study include: the College of Life Sciences, Beijing Normal University and the Wuhan Institute of Physics and Mathematics at the China Academy of Sciences in Wuhan, China.



 back to list | back to top